Alnylam: Q4 Earnings Snapshot

Associated Press Finance
1 min read
0
In this article:

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $137.9 million in its fourth quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.10.

The results exceeded Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share.

The RNA interference drug developer posted revenue of $439.7 million in the period, missing Street forecasts. Eleven analysts surveyed by Zacks expected $445.6 million.

For the year, the company reported that its loss narrowed to $440.2 million, or $3.52 per share. Revenue was reported as $1.83 billion.

Alnylam shares have dropped 14% since the beginning of the year. The stock has decreased 27% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Advertisement

Recommended Stories